ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Prostate Cancer Target Analyzed

Molecular Structure: Detailed view of cancer-related cytochrome P450 could aid drug design

by Stu Borman
January 30, 2012 | APPEARED IN VOLUME 90, ISSUE 5

[+]Enlarge
Credit: Nature
Structure of cytochrome P450 17A1, with prostate cancer drug abiraterone (center, mostly black) bound to the enzyme’s heme iron (sphere).
09005-notw3-P450enzymecxd.jpg
Credit: Nature
Structure of cytochrome P450 17A1, with prostate cancer drug abiraterone (center, mostly black) bound to the enzyme’s heme iron (sphere).

To understand better how two new anticancer agents work, researchers have obtained the first X-ray structures of a key cytochrome P450 enzyme to which they bind. Understanding how the drugs inhibit the enzyme could aid the design of more effective medications for prostate and breast cancer with fewer side effects.

Cytochrome P450 17A1 (CYP17A1) is found in cell membranes in the human reproductive tract and adrenal gland, where it catalyzes sequential hydroxylase and lyase reactions in the biosynthesis of testosterone and other sex hormones. The approved Janssen Biotech drug abiraterone (Zytiga) and the Tokai Pharmaceuticals agent TOK-001 (Galeterone), which is in clinical trials, are prostate cancer treatments that work by inhibiting both the enzyme’s lyase activity, accounting for most of their efficacy, and its hydroxylase activity, which causes side effects.

Emily E. Scott, an associate professor of medicinal chemistry, and Natasha M. DeVore at the University of Kansas have obtained X-ray structures by getting CYP17A1 to crystallize with each of these drugs bound (Nature, DOI: 10.1038/nature10743).

The structures reveal that the drugs bind to the enzyme in a manner far different from what scientists expected. Modeling studies had suggested the drugs would orient parallel to the plane of the enzyme’s active-site heme group; instead, the drugs are nearly perpendicular to it.

Other P450 enzymes have been analyzed structurally, says cytochrome P450 specialist Paul Ortiz de Montellano of the University of California, San Francisco. But the new structures are “particularly important” in the search for prostate and breast cancer drugs with fewer side effects. For instance, they could lead to medications highly selective for CYP17A1, one of 57 similar P450 enzymes found in humans.

Scott says her group is collaborating with that of University of Kansas synthetic chemist Jeffrey Aubé “to design new compounds we hope will be more-selective drugs”—by inhibiting the enzyme’s lyase but not its hydroxylase activity, for example.

Advertisement
X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment